It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

When you buy through our links, we may earn a commission. Learn more› By Caira Blackwell and Joanne Chen If you’re a side-sleeper, congratulations! According to the Mayo Clinic, side sleeping ...

And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...

Shares of Moderna Inc. MRNA slid 1.96% to $34.46 Tuesday ... Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation ...

To treat nasal congestion, your doctor may recommend an OTC steroid nasal spray. They have few side effects and can really improve your stuffy nose. Like antihistamines, doctors usually recommend ...

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 ...